ClinicalTrials.gg
RecruitingNCT07243561EXO-ASDUpdated Oct 16, 2026

Prospective Clinical Study on Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Childhood Autism

A Phase 1/2 interventional study of hUC-MSC-Exos Nasal Spray in Autism Spectrum Disorder (ASD and Prospective Study, sponsored by Dongfang People's Hospital. Recruiting at 1 site in China. Open to participants aged 3 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Dongfang People's Hospital · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
3 Years to 7 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Autism Spectrum Disorder with a site in China — 37 open to participants now, 38 under way, none of them phase 3. Autism Spectrum Disorder · China.

Planned enrollment
43rd of 63
60 · median 96
Started
2025
with 18 others
Phase 1/2
2 of 86
2 open now
Primary completion
2026-10
later than 17 of 37 live
Registered
64th of 86
by date

Among the 86 studies in Autism Spectrum Disorder with a site in China, this one is the 43rd largest by planned enrollment of the 63 interventional ones that give a count, is one of 19 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 17 of the 37 other live ones, and was the 64th registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

37 of the 86 studies in Autism Spectrum Disorder with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.

This study: 3 Years to 7 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Autism Spectrum Disorder with a site in China, or all of them as a file.
02

Study summary

This clinical study aims to evaluate whether a nasal spray containing exosomes derived from human umbilical cord mesenchymal stem cells (hUC-MSC-EXOs) can safely and effectively improve core symptoms in children aged 3-7 years with autism spectrum disorder (ASD). It is a 24-week, non-randomized, controlled, open-label trial. Sixty pediatric patients with ASD will be non-randomly assigned at a 1:2 ratio to two groups: a no-intervention control group and an active exosome nasal spray treatment group. The treatment group will receive the nasal spray every other day, totaling 10 administrations throughout the study. The no-intervention control group will receive no experimental treatment but will undergo the same assessments and safety checks with the treatment group. This design aims to monitor the safety and efficacy of the hUC-MSC-EXOs nasal spray.

03

Conditions studied

  • Autism Spectrum Disorder (ASD
  • Prospective Study

Keywords

  • Autism Spectrum Disorder
  • umbilical cord mesenchymal stem cells
  • exosome
04

Who can participate

Ages eligible
3 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis meets the ICD-11 ASD criteria or ASD clinical diagnostic standards.
  • No significant improvement in core symptoms was observed after ≥3 months of standardized behavioral intervention.
  • Score ≥30 on the CARS2, indicating mild-to-moderate or more severe autism.
  • Aged 3 (inclusive) to 7 (inclusive) years, regardless of gender
  • Voluntary participation in this clinical study, with written provided by the patient's legal guardian, and willingness to undergo examinations, treatment, and cooperate with follow-up visits.
  • In the investigator's judgment, the patient is capable of understanding and complying with study requirements.

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic reactions.
  • Any severe mental disorder or other types of autism spectrum disorders.
  • History of epileptic seizures within the past six months.
  • Autism secondary to epilepsy, cerebrovascular disease, or traumatic brain injury.
  • Disease severity rated as normal, borderline mental disorder, or mild mental disorder on the Clinical Global Impression scale.
  • Moderate or severe extrapyramidal symptoms or tardive dyskinesia.
  • Severe self-injurious behavior.
  • Active systemic or severe localized infections, including , syphilis, and hepatitis.
  • diseases.
  • Major organ impairment.
  • Severe pulmonary or hematological diseases, , or immunodeficiency.
  • Concurrent treatments that may interfere with the safety and efficacy evaluation of stem cell therapy.
  • Participation in other clinical trials within the past three months.
  • Other clinical conditions deemed by investigators as unsuitable for study inclusion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    hUC-MSC-EXOs Nasal Spray Group

    Biological: hUC-MSC-Exos Nasal Spray

  • No intervention
    No-Intervention Control Group

Interventions

  • BiologicalhUC-MSC-Exos Nasal Spray

    The total therapeutic dosage is set at 400 billion hUC-MSC-EXOs particles. Each nasal administration delivers 40 billion particles, with a total of 10 administrations completing the full course. The treatment is administered on an alternate-day schedule.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Related Adverse Events

    The incidence of treatment-related adverse events will be assessed and graded according to the Common Terminology Criteria for Adverse Events version 5.0. The number of participants experiencing any treatment-related adverse event will be recorded and reported.

    Time frame: Week 2, Week 6, Week 24

  2. Childhood Autism Rating Scale, Second Edition (CARS-2) Score

    Scale Description: The CARS-2 is a 15-item behavior rating scale used to diagnose and assess the severity of ASD. Range of Scores: 15 to 60. Interpretation: A higher score indicates a worse outcome.

    Time frame: Week 6, Week 24

Secondary outcomes

  1. Autism Behavior Checklist (ABC)

    Scale Description: The ABC is a 57-item checklist used to screen for and assess behaviors associated with ASD. Range of Scores: 0 to 158. Interpretation: A higher score indicates a worse outcome.

    Time frame: Week 6, Week 24

  2. Serum Level of Tumor Necrosis Factor-Alpha (TNF-α)

    Serum concentration of the inflammatory cytokine TNF-α. The unit of measure is pg/mL.

    Time frame: Week 6, Week 24

07

Study locations

1 of 1 sites recruiting
  • Dongfang People's Hospital
    Dongfang, Hainan, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 13 months after the start.

Primary completion moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Oct 16, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 24, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Oct 30, 2026was Aug 2026
CompletionEst.
Oct 30, 2026was Aug 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 30, 2026→Oct 30, 2026
moved 2 times, Sep 25, 2026 – Oct 16, 2026
Study completion
Aug 30, 2026→Oct 30, 2026
moved 2 times, Sep 25, 2026 – Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    Primary completion Oct 1, 2026→Oct 30, 2026
    Study completion Oct 1, 2026→Oct 30, 2026
  2. Sep 25, 2026
    Primary completion Aug 30, 2026→Oct 1, 2026
    Study completion Aug 30, 2026→Oct 1, 2026
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07243561
Lead sponsor
Dongfang People's Hospital
Collaborators
Shanghai Tongjin Stem Cell Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Sep 1, 2025
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Zhongmin Liu
Contact
dfsrmyykjk@126.com
+86-0898-38932608

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion